Dengue Treatment Market by Drug Class (NSAIDS, Antibiotics, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Dengue Treatment Market size was valued at USD 324.3 million in 2022 and is growing at a CAGR of 13.6% from 2023 to 2029. The global market provides a detailed overview and that can be segmented by drug class and by distribution channel. By drug class, the global dengue treatment market has been segmented into NSAIDS, Antibiotics, and Corticosteroids. The NSAIDs dengue treatment segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. Based on the distribution channel, the segment has been segregated into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The Hospital pharmacies segment is expected to dominate other segments in the global dengue treatment market. The retail pharmacies segment is expected to witness the highest CAGR during the forecast period according to precision business insights. Dengue fever is also known as break bone fever is mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several species of mosquitos of the Aedes type, principally A. aegypti. Symptoms of dengue include fever, headache vomiting, muscle and joint pains, and characteristic skin rash. On infection of dengue, patient will automatically recover within seven days. But in some cases, it may develop to life threatening dengue haemorrhagic fever. The virus has five different types of strains, infection with one strain usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications.

Dengue Treatment Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Dengue Treatment Market Dynamics Dynamics

The dengue treatment market anticipated surging its growth owing to rise in dengue burden in tropical and sub-tropical regions, increased government funding to fight against dengue, and unmet market needs of managing dengue burden around the world. In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. However, lack or insufficient healthcare infrastructure in underdeveloped and developing regions leading to serious medical conditions going unnoticed. Furthermore, lack of awareness related to symptoms and the high-cost of treatment are hindering the dengue-treatment market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Dengue Treatment Market Segmentation

By Drug Class
  • Antibiotics
  • Corticosteroids
By distribution channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
By Geography

North America

  • US
  • Canada


  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe


  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA


Frequently Asked Questions

The fastest-growing segment of the global dengue treatment market is hospital pharmacies due to large patient base and prescribed medicine in hospitals.

The laboratory automation is the current trend in the dengue treatment market due to fast and accurate diagnosis and treatment.

Necessity of dengue treatment in urban areas and the strategic initiatives by market players are creating new opportunities in the dengue treatment market.

The lack or insufficient healthcare infrastructure in underdeveloped and developing regions leading to serious medical conditions going unnoticed. Furthermore, lack of awareness related to symptoms and the high-cost of treatment may hamper the global market growth.

  • Roche AG
  • Sun Pharmaceutical Industries Limited
  • Abbivax
  • Takeda Pharmaceutical Company
  • Merck & Co Inc.